Prior to joining Hopewell as Chief Scientific Officer in 2022, Dr. Zhang served as VP of Biological Development at Editas Medicine, where she led the cross functional teams employing breakthrough CRISPR-based in vivo and ex vivo gene editing technology, bringing AAV gene therapy in ophthalmology and autologous cell therapies in hematology from program inception to three successful IND submissions. Previously, Dr. Zhang was the Senior Director of Global R&D Platforms and Global Pharmaceutical Development at Genzyme and Sanofi. As the portfolio head of global translational science, she was responsible for rare genetic diseases and contributed to the approval and commercialization of Cerezyme, Fabrazyme, Myozyme/Lumizyme, Thyrogen, Cerdelga, Lemtrada and Zenpozyme. Dr. Zhang began her career as a postdoctoral fellow at the National Heart, Lung and Blood Institute at NIH. She has co-authored more than 70 peer-reviewed scientific articles and co-invented multiple issued U.S. patents. She received her B.S. from Tsinghua University, Beijing, China, her M.Sc. from the Chinese Academy of Science and her Ph.D. from Queen’s University, Canada.
